Alterity Therapeutics Limited (ATHE)
ATHE Stock Price Chart
Explore Alterity Therapeutics Limited interactive price chart. Choose custom timeframes to analyze ATHE price movements and trends.
ATHE Company Profile
Discover essential business fundamentals and corporate details for Alterity Therapeutics Limited (ATHE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Sept 2003
Employees
10.00
Website
https://alteritytherapeutics.comCEO
David A. Stamler
Description
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
ATHE Financial Timeline
Browse a chronological timeline of Alterity Therapeutics Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Aug 2026
EPS estimate is -$0.15, while revenue estimate is $2.48m.
Earnings released on 25 Feb 2026
EPS came in at -$0.38 falling short of the estimated -$0.23 by -65.91%, while revenue for the quarter reached $645.88k , missing expectations by -39.60%.
Earnings released on 28 Aug 2025
EPS came in at -$0.40 surpassing the estimated -$0.43 by +7.21%, while revenue for the quarter reached $3.83m , missing expectations by -24.11%.
Earnings released on 4 Aug 2025
Earnings released on 28 Feb 2025
EPS came in at -$0.00 surpassing the estimated -$0.53 by +99.87%, while revenue for the quarter reached $802.96k , missing expectations by -65.14%.
Earnings released on 3 Feb 2025
EPS came in at -$0.00 , while revenue for the quarter reached $802.96k .
Earnings released on 29 Aug 2024
EPS came in at -$0.00 surpassing the estimated -$0.05 by +96.21%, while revenue for the quarter reached $2.12m , beating expectations by +123.01%.
Earnings released on 11 Apr 2024
EPS came in at -$0.00 , while revenue for the quarter reached $1.06m .
Earnings released on 28 Feb 2024
EPS came in at -$0.00 surpassing the estimated -$0.11 by +97.53%, while revenue for the quarter reached $1.90m , beating expectations by +98.35%.
Earnings released on 30 Jan 2024
EPS came in at -$0.00 , while revenue for the quarter reached $950.36k .
Earnings released on 30 Jun 2023
EPS came in at -$0.00 , while revenue for the quarter reached $1.53m .
Earnings released on 31 Mar 2023
EPS came in at -$0.00 surpassing the estimated -$0.12 by +99.01%, while revenue for the quarter reached $765.25k , missing expectations by -48.96%.
Earnings released on 28 Feb 2023
EPS came in at -$1.11 surpassing the estimated -$1.81 by +38.62%, while revenue for the quarter reached $7.67k , missing expectations by -99.58%.
Stock split effective on 9 Jan 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Dec 2022
EPS came in at -$0.00 , while revenue for the quarter reached $2.39m .
Earnings released on 30 Aug 2022
EPS came in at -$1.43 surpassing the estimated -$1.97 by +27.48%, while revenue for the quarter reached $1.82m , missing expectations by -36.46%.
Earnings released on 30 Jun 2022
EPS came in at -$0.00 , while revenue for the quarter reached $2.76m .
Earnings released on 28 Feb 2022
EPS came in at -$0.98 , while revenue for the quarter reached $980.00 .
Earnings released on 31 Dec 2021
EPS came in at -$0.00 , while revenue for the quarter reached $2.36m .
Earnings released on 31 Aug 2021
ATHE Stock Performance
Access detailed ATHE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
